Regenerative Medicine: Could This Be Healthcare's Saving Grace?
..Knee Replacements will be Unnecessary in the Next Five Years Cell therapy makes up over 60% of the regenerative medicine market, most of which is in the area of stem cell therapy. Adult stem cells can be used in the areas of cardiology; musculo-skeletal, including neurology; optometry; dermatology; cosmology; wound healing; and cancer. Stem cell therapy, when combined with immune and gene therapy, shows even greater potential to cure diseases. This new combination of regenerative cell therapies will open a new age of medicine, forever changing how it is practiced. For example, in the future, knee replacements may no longer be needed with regenerative cell therapy. Regenerative medicine is not only driven by new evidence indicating these therapies are capable of curing diseases, but also by the fact that the world’s population is aging.
- CAP -1002; a leading product using cardiosphere-derived cells to treat post-myocardial infarction (heart attack), advanced heart failure, and Duchenne Muscular Dystrophy. Big Pharma Investments Big in Regeneration Medicine Big Pharma cannot be left out of this race. Many companies have become interested in regenerative medicine. Pharmaceutical companies are building relationships with innovating regenerative medicine companies. Pfizer PFE +0% Pfizer has created its own unit, Neusentis, in Massachusetts, U.S. Neusentis’ main focus is to develop cell-based therapies for age-related macular degeneration. Celgene and Teva Pharma Celgene has a 4.5% stake in Mesoblast to develop an Acute Graft Versus Host Disease (GVHD) program. Teva Pharma holds a 20% stake in Mesoblast and is a major partner in the Chronic Congestive Heart Failure (CCHF) program, in phase III clinical trials. Johnson & Johnson Johnson & Johnson invested 12.5 million in Capricor Therapeutics (CAPR) for support in a stem cell therapy program. The investment could increase to $325 million, depending on milestone attainment. The program has also received $20 million from the California Institute for Regenerative Medicine. Phase II trials for treatment of cardiovascular disease have been scheduled. The global healthcare consumer demand for stem cell therapies is very high, with stem cell therapy tourism gaining popularity - mostly from the U.S. Globally, many stem cell therapies are not clinically proven or tested, with only a few resulting in positive clinical results. These international clinics are charging anywhere from $20,000 to $100,000 per treatment, and they are not covered by insurance.
$LAHO.. affluent, are avoiding primary care and selecting regenerative care. Why not use your own stem cells to heal yourself. Nature has the cure positioned without 2 miles of the poison. Cash business, even when financed GSCG collects, Banks printing money no limits, ceiling lifted.
Market Data 
Markets 
AI
